title: Overview of current and upcoming strategies implied for the therapy of type 2 diabetes mellitus.
abstract: Population explosion, urbanization, changes in lifestyle management, improper food habits and various other factors play focal contributors in the massive prevalence of type 2 diabetes mellitus in the developing countries. Although insulin is the cornerstone in the management of type 1 diabetes; insulin, anti-hyperglycemic and hypoglycemic agents are proved to be effective in type 2 diabetes, although their efficacy decreases with the progress of the disease. Moreover a significant number of side effects, mostly hypoglycemia and weight gain have put a bar in using these drugs confidently. Many novel therapeutic strategies with convincing efficacy and less adverse effects are currently emerging for providing efficient means of treatment of this disorder. This article mainly focuses on newer and unconventional pharmaceutical or biotechnical strategies that may or may not have been implied for the treatment of Type 2 Diabetes mellitus on a widescale basis so far. These strategies are supposed to be efficient in controlling glycemic levels and possess a significant potential to reduce the co-morbidities associated with this disease.
authors.forename: Sayantan Roy
authors.initials: SR
authors.lastname: Choudhury
authors.forename: Ankur
authors.initials: A
authors.lastname: Datta
authors.forename: Sunirmal
authors.initials: S
authors.lastname: Chanda
authors.forename: A N
authors.initials: AN
authors.lastname: Pathak
authors.affiliation: Amity Institute of Biotechnology (AIB), Amity University Rajasthan (AUR), Jaipur, India. srchoudhury2014@gmail.com.
authors.forename: Saibal
authors.initials: S
authors.lastname: Das
mesh_terms: D001559:Benzhydryl Compounds / Q000008:administration & dosage; D003906:Developing Countries; D003924:Diabetes Mellitus, Type 2 / Q000453:epidemiology / Q000517:prevention & control*; D004359:Drug Therapy, Combination; D005247:Feeding Behavior; D005960:Glucosides / Q000008:administration & dosage; D007722:Health Knowledge, Attitudes, Practice; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage*; D007294:Inositol / Q000008:administration & dosage / Q000031:analogs & derivatives; D054833:Isoindoles / Q000008:administration & dosage; D036103:Nanotechnology / Q000639:trends*; D015995:Prevalence; D040242:Risk Reduction Behavior; D033581:Stem Cell Transplantation; D014507:Urbanization
chemical_list: D001559:Benzhydryl Compounds; D005960:Glucosides; D007004:Hypoglycemic Agents; D054833:Isoindoles; C529054:dapagliflozin; D007294:Inositol; C087255:mitiglinide; C102817:voglibose